Alzheimer's Research & Therapy

CORRECTION Open Access

Correction: ^{18}F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis

Sébastien Heyer[1], Maïa Simon[2], Matthieu Doyen[1,3], Ali Mortada[1], Véronique Roch[1], Elodie Jeanbert[2], Nathalie Thilly[2], Catherine Malaplate[4], Anna Kearney-Schwartz[5,6], Thérèse Jonveaux[6,7], Aurélie Bannay[8] and Antoine Verger[1,3*]

Correction: ***Alz Res Therapy*** **16, 182 (2024)**
https://doi.org/10.1186/s13195-024-01535-3

Following publication of the original article [1], corrections were made to the three numbers (1), (2), (3) in Methods section of Abstract that were incorrectly presented as reference citations: (Prince M, Wimo A, Guerchet Maëlenn, Ali G-C, Wu Y-T et al. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. [Research Report] Alzheimer's Disease International. 2015. 2015.); (Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–62.) and (Davis M, O`Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. CAR. 2018;15(8):777–88.).

The original article [1] has been updated.

Published online: 13 November 2024

References

1. Heyer S, Simon M, Doyen M, et al. ^{18}F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. Alz Res Therapy. 2024;16:182. https://doi.org/10.1186/s13195-024-01535-3.

Publisher's note

The online version of the original article can be found at https://doi.org/10.1186/s13195-024-01535-3.

*Correspondence:
Antoine Verger
a.verger@chru-nancy.fr
[1]Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, Nancy F-54000, France
[2]Department of Methodology, Promotion and Investigation, Université de Lorraine, CHRU-Nancy, Nancy F-54000, France
[3]Université de Lorraine, IADI, INSERM U1254, Nancy F-54000, France
[4]Department of Biochemistry, Université de Lorraine, CHRU-Nancy, Nancy F-54000, France
[5]Department of Geriatrics, Université de Lorraine, CHRU-Nancy, Nancy F-54000, France
[6]CMRR, University Hospital Nancy, Nancy F-54000, France
[7]Department of Neurology, University Hospital Nancy, Nancy F-54000, France
[8]Medical Assessment and Information Department, Université de Lorraine, CHRU-Nancy, Nancy 54000, France